Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer

Registry ID

EUCTR2009-017591-24

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

Eli Lilly and Company

Start date

2010-02-23

Completion date

2012-06-29

Last update

2026-08-16

Conditions

• Locally advanced or metastaic non-small cell lung cancer, second line therapy
• Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Summary

The primary objective of the study is to evaluate the anti-tumor activity of LY2181308 in combination with docetaxel therapy (experimental arm) compared to docetaxel alone (control or standard-of-care arm) in second line Non Small Cell Lung Cancer (NSCLC) patients.

Locations

• , , Belgium
• , , Italy
• , , UK
• , , Germany

Related clinical trials

• Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

View on source registry